Riskpilot← Back to searchSign inGet full accessOXELL & CO AB
ABActiveOrg 5566236948Lilla Nygatan 11General medical practice activities · NACE 8621Est. 20021-4 employees
Revenue 2025
SEK 4,7M
+3% vs 2024
EBITDA margin
51.5%
+83% vs 2024
Equity ratio
43.9%
Financial strength
Net profit 2025
SEK 1,3M
+45% vs 2024
| Revenue | SEK 4,7M | +3% |
| EBITDA | SEK 2,4M | +83% |
| Net profit | SEK 1,3M | +45% |
| Total assets | SEK 4,6M | +18% |
| Equity | SEK 2M | +22% |
| Employees | — | — |
Legal name
OXELL & CO AB
Org number
5566236948
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
6 februari 2002
Share capital
SEK 100 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva läkarverksamhet med medicinsk utbildning och forskning, översättningsuppdrag. Bolaget skall även äga och förvalta fast och lös egendom, företrädesvis värdepapper samt därmed förenlig verksamhet. Uthyrning av personal.Uppfödning och försäljning av hästar.
Address
Lilla Nygatan 11
Phone
+46859147591
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4 016 | 3 678 | 4 076 | 4 522 | 4 652 |
| Staff expenses | — | — | −1 805 | — | −1 337 |
| EBITDA | 229 | 1 515 | 1 682 | 1 313 | 2 398 |
| Depreciation & amort. | −173 | −110 | −96 | −191 | −210 |
| EBIT | 56 | 1 405 | 1 586 | 1 122 | 2 188 |
| Net financials | — | −1 | −2 | 54 | −148 |
| Profit before tax | 118 | 1 232 | 1 372 | 1 192 | 1 703 |
| Tax | −28 | −260 | −322 | −266 | −364 |
| Net profit | 90 | 972 | 1 051 | 926 | 1 339 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 627 | 3 912 | 4 661 | 3 870 | 4 550 |
| Equity | 1 242 | 1 714 | 2 065 | 1 642 | 1 996 |
| Long-term debt | 0 | 0 | — | 0 | — |
| Short-term debt | 757 | 398 | 584 | 231 | 220 |
| Total debt | 757 | 398 | 584 | 231 | 220 |
EBITDA margin
51.5%
This company
15.8%
Market median
+226% vs market
20212025
Equity ratio
43.9%
This company
38.2%
Market median
+15% vs market
20212025
Return on equity
67.1%
This company
18.4%
Market median
+265% vs market
20212025
Net profit margin
28.8%
This company
8.1%
Market median
+256% vs market
20212025
Asset turnover
1.02×
This company
1.12×
Market median
+9% vs market
20212025
Debt / equity
1.28×
This company
0.62×
Market median
-106% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
NP Audit | Audit | 2024 |
| Former (1) | ||
BN | Audit | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of OXELL & CO AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bengt Niclas Valdemar Frank | Audit | 0 companies |
| Nikola Pljevaljcic | Audit | 0 companies |
| Anna Kristine Oxell | Board of Directors | 0 companies |
| Hannah Julia Kamomill Oxell | Deputy Board Member | 0 companies |